Hemab Therapeutics Holdings, Inc. IPO
Hemab Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hemophilia and other bleeding disorders. The company's pipeline addresses significant unmet medical needs in rare hematologic conditions, which has attracted investor interest in the specialized biopharma sector.
Key Facts
| Industry | Biotechnology |
| Funding | $212 million raised in April 2026 U.S. IPO; backed by Novo Nordisk |
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a biopharmaceutical company developing therapies for patients with hemophilia and related bleeding disorders. Hemophilia is a rare genetic disorder that impairs the body's ability to form blood clots, leading to prolonged bleeding episodes that can be life-threatening without treatment.
The hemophilia treatment landscape has evolved significantly in recent years, with new extended half-life factor replacement therapies, gene therapies, and non-factor treatments expanding options for patients. Companies developing innovative approaches in this space compete for market share in a specialized but commercially attractive rare disease segment.
Detailed information about Hemab Therapeutics' specific drug candidates, clinical trial status, and competitive positioning is limited in publicly available sources. The company's development programs would need to demonstrate differentiation from existing approved therapies and those in late-stage development to attract investor interest in public markets.
IPO Status
Hemab Therapeutics Holdings, Inc. completed its initial public offering in April 2026, launching on U.S. markets as part of a resurgence in biotech IPO activity. The company, which is backed by Novo Nordisk, raised $212 million in its U.S. IPO, providing significant capital to advance its clinical pipeline targeting bleeding disorders with a focus on novel therapeutic approaches for hemophilia patients. The IPO traded under the ticker symbol COAG. The successful IPO reflects improved market conditions for biotechnology companies after several challenging years of limited investor appetite. Hemab's listing coincided with other biotech IPOs including Seaport, signaling gathering momentum in the sector. The substantial funding raised positions the company to advance late-stage clinical trials and move toward potential commercialization of its hemophilia therapies, representing the broader trend of specialized rare disease-focused biotechs accessing public market capital.
Competitors
Frequently Asked Questions
Does Hemab Therapeutics Holdings, Inc. have a stock?
Hemab Therapeutics has not yet had an IPO. The company is a private clinical-stage biopharmaceutical firm that may pursue public markets to fund continued development of its hemophilia therapies. Sign up for alerts to stay informed.
When is the Hemab Therapeutics Holdings, Inc. IPO date?
No IPO date has been announced for Hemab Therapeutics. Biotech IPO timing typically depends on clinical milestones, market conditions, and capital needs. Sign up for alerts to stay informed.
How can I buy Hemab Therapeutics Holdings, Inc. stock?
Hemab Therapeutics stock is not currently available for public purchase as the company remains private. If an IPO occurs, shares would become available through brokerage accounts on a major exchange. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts